---
title: "In \"The Big Banks,\" Citigroup: Last year's birth rate in China fell short of expectations, expecting intensified competition in the infant formula market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273023668.md"
description: "The Lyon Research Report points out that the number of births in China will be 7.92 million in 2025, lower than expected, and competition in the infant formula market is expected to intensify. The milk powder market size will remain flat in 2025, with a projected decline of 3% in 2026. The lower-than-expected birth rate means that companies need to pay attention to product structure and sales momentum. Lyon prefers YILI and H&H INTL HLDG, giving them an \"outperform\" rating, with target prices of RMB 34, HKD 16.4, and HKD 4.9, respectively"
datetime: "2026-01-20T02:57:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273023668.md)
  - [en](https://longbridge.com/en/news/273023668.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273023668.md)
---

# In "The Big Banks," Citigroup: Last year's birth rate in China fell short of expectations, expecting intensified competition in the infant formula market

Citi published a research report indicating that the National Bureau of Statistics recently announced that China's birth population in 2025 will be 7.92 million, lower than the bank and milk powder manufacturers' expectations. Considering the high base in 2024, the year-on-year decline in the birth population reached 17%. The bank currently predicts that the milk powder market size in 2025 will remain roughly flat year-on-year. Taking into account the 2025 birth population data, the increase in marriage registrations, and the average selling price growth under the ongoing trend of premiumization, it forecasts that the milk powder market size will decline by 3% year-on-year in 2026.

Citi pointed out that the lower-than-expected birth numbers mean that competition in the infant formula market will intensify. For companies, product structure and sales momentum are crucial. As the birth peak in 2024 gradually shifts to stage 3 products, companies with a stable customer base and the ability to gain consumer trust in stage 1 and stage 2 products are believed to benefit more from existing customers extending their purchases to stage 3 products.

Citi prefers YILI (600887.SH) and H&H INTL (01112.HK) over China Feihe (06186.HK), giving each an "Outperform" rating, with target prices of RMB 34, HKD 16.4, and HKD 4.9, respectively

### Related Stocks

- [01112.HK](https://longbridge.com/en/quote/01112.HK.md)
- [159843.CN](https://longbridge.com/en/quote/159843.CN.md)
- [600887.CN](https://longbridge.com/en/quote/600887.CN.md)

## Related News & Research

- [ZAWYA: Hany Arram during his participation in the 9th edition of “The Marketers League” at the Grand Egyptian Museum](https://longbridge.com/en/news/286071699.md)
- [H&H Delivers Strong Q1 Revenue Growth on China-Driven Nutrition Demand and Deleveraging](https://longbridge.com/en/news/283636437.md)
- [12:46 ETEyePromise Introduces Heyedrate™ Clinical: A Next Generation Artificial Tear](https://longbridge.com/en/news/286800296.md)
- [11:00 ETPureance Hydralift Reviews (2026 Official Report): Authentic Ingredients, Benefits, and Verified Results](https://longbridge.com/en/news/286648607.md)
- [16:51 ETBeverly Hills MD ProRetinol Age Rewind x3 Officially Launches: A New Era of Gentle, Slow-Released Retinol Skincare Backed by Plastic Surgeons](https://longbridge.com/en/news/286966075.md)